Abstract
To evaluate dose levels for semaglutide, a glucagon-like peptide-1 analogue approved for the treatment of type 2 diabetes, by examining the effects of demographic factors on efficacy and safety in an exposure-response analysis. We analysed data from 1552 adults from four randomized phase III trials of 30 to 56 weeks' duration, investigating once-weekly semaglutide doses 0.5 and 1.0 mg. Exposure-response relationships were investigated using graphical and model-based techniques to assess the two dose levels and subgroups with the highest and lowest exposure and response. The population had the following demographic characteristics: baseline mean age between 53.2 and 58.4 years, glycated haemoglobin (HbA1c) between 64 and 67 mmol/mol (8.0% and 8.3%), body weight between 71.3 and 96.2 kg, and diabetes duration between 4.2 and 8.9 years. Exposure-response analysis showed a clear HbA1c and weight reduction across exposures after 30 weeks, irrespective of baseline values. The exposure-response for HbA1c was influenced by baseline HbA1c, and body weight exposure-response was influenced by sex, with limited impact of other factors. Analyses for relevant subgroups of baseline body weight, baseline HbA1c and sex indicated clinically rele...Continue Reading
References
Mar 21, 1998·The Journal of Clinical Investigation·A FlintJ J Holst
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Jun 17, 2006·Diabetes, Obesity & Metabolism·L BlondeD M Kendall
Nov 14, 2006·Lancet·Daniel J Drucker, Michael A Nauck
Oct 12, 2007·Physiological Reviews·Jens Juul Holst
Dec 24, 2011·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Robert R HenryRichard E Pratley
Mar 22, 2012·Current Clinical Pharmacology·Giuseppe Derosa, Pamela Maffioli
Jan 4, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Aug 15, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M E J LeanUNKNOWN NN8022-1807 Investigators
Jan 29, 2014·Endocrinology·Charles PykeLotte Bjerre Knudsen
May 24, 2014·Circulation Research·John R Ussher, Daniel J Drucker
Nov 7, 2014·Diabetes Technology & Therapeutics·Feng SunLuwen Shi
Dec 6, 2014·Journal of Clinical Pharmacology·Christoph KapitzaAnne Flint
Aug 27, 2015·Journal of Medicinal Chemistry·Jesper LauThomas Kruse
Nov 5, 2015·CPT: Pharmacometrics & Systems Pharmacology·R V OvergaardC W Tornøe
Feb 3, 2016·Diabetes, Obesity & Metabolism·J P H WildingC W le Roux
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Jan 7, 2017·Diabetes, Obesity & Metabolism·Michael HorowitzChris K Rayner
Jan 24, 2017·The Lancet. Diabetes & Endocrinology·Christopher SorliStephen C Bain
Mar 28, 2017·The Lancet. Diabetes & Endocrinology·Vanita R ArodaJ Hans DeVries
Apr 8, 2017·The Lancet. Diabetes & Endocrinology·Bo AhrénFrancis Chow
Dec 17, 2017·Diabetes Care·Andrew J AhmannVanita R Aroda
Dec 28, 2017·Diabetes Care·Laszlo HegedüsUNKNOWN LEADER Publication Committee on behalf of the LEADER Trial Investigators
Jan 13, 2018·Diabetes, Obesity & Metabolism·Kohei KakuArihiro Kiyosue
Citations
Jul 27, 2018·Diabetes, Obesity & Metabolism·Rune V OvergaardDesirée Thielke
Feb 16, 2019·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·Georgios A ChristouDimitrios N Kiortsis
Feb 23, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Rune V OvergaardSteen H Ingwersen
Jul 31, 2020·JCI Insight·Francis S WillardKyle W Sloop
Nov 18, 2020·BMJ Open·Richard E PratleyAdie Viljoen
Oct 30, 2020·BMJ Open Diabetes Research & Care·Ildiko LingvayJohn Wilding
Mar 31, 2021·Clinical Pharmacokinetics·Andreas B JordyTine A Bækdal
May 11, 2021·Clinical Pharmacokinetics·Rune V OvergaardRasmus Juul Kildemoes
Jul 22, 2021·Diabetes, Obesity & Metabolism·Richard E PratleyNino Miresashvili